ArticleChembiochem : a European journal of chemical biology2016
New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.
Article in Chembiochem : a European journal of chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 89 citations in OpenAlex.
- LinTT1-Functionalized Hybrid Lipid-Polymer Nanoparticles for Glioblastoma Targeting.ACS pharmacology & translational science · 2025Article
- Effects of LinTT1-peptide conjugation on the properties of poly(ethylene glycol)-block-(ε-caprolactone) nanoparticles prepared by the nanoprecipitation method.Drug delivery and translational research · 2025Article
- Advancing Cancer-Targeted Nanotherapies with Tumor Homing Peptides.ACS pharmacology & translational science · 2025Review
- Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation.Drug delivery and translational research · 2024Article
- Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.Scientific reports · 2024Article
- Review
- Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands.Journal of nanobiotechnology · 2024Review
- In Silico and In Vivo Studies of a Tumor-Penetrating and Interfering Peptide with Antitumoral Effect on Xenograft Models of Breast Cancer.Pharmaceutics · 2023Article
- Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells.Frontiers in oncology · 2023Article
- Role of gC1qR as a modulator of endothelial cell permeability and contributor to post-stroke inflammation and edema formation.Frontiers in cellular neuroscience · 2023Review
- gC1qR: A New Target for Cancer Immunotherapy.Frontiers in immunology · 2023Review
- Metabolic Labeling-Based Chemoproteomics Establishes Choline Metabolites as Protein Function Modulators.ACS chemical biology · 2022Article
- Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue.Cancers · 2022Review
- CoreNanoscale advances · 2022Article
- Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides.Methods in molecular biology (Clifton, N.J.) · 2022Article
- C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response.Frontiers in physiology · 2022Review
- PL1 Peptide Engages Acidic Surfaces on Tumor-Associated Fibronectin and Tenascin Isoforms to Trigger Cellular Uptake.Pharmaceutics · 2021Article
- p32 promotes melanoma progression and metastasis by targeting EMT markers, Akt/PKB pathway, and tumor microenvironment.Cell death & disease · 2021Article
- Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma.Pharmaceutics · 2021Article
- Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
Cell surface p32, the target of LyP-1 homing peptide, is upregulated in tumors and atherosclerotic plaques and has been widely used as a receptor for systemic delivery of payloads. Here, we identified an improved LyP-1-mimicking peptide (TT1, CKRGARSTC). We used this peptide in a fluorescence polarization-based high-throughput screening of a 50,000-compound chemical library and identified a panel of compounds that bind p32 with low micromolar affinity. Among the hits identified in the screen, two compounds were shown to specifically bind to p32 in multiple assays. One of these compounds was chosen for an in vivo study. Nanoparticles surface-functionalized with this compound specifically adhered to surfaces coated with recombinant p32 and, when injected intravenously, homed to p32-expressing breast tumors in mice. This compound provides a lead for the development of p32-targeted affinity ligands that circumvent some of the limitations of peptide-based probes in guided drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.